title: CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
abstract: Expression of cytokine receptor-like factor 2 (CRLF2) has recently been shown to be upregulated as well as mutated in populations of B-progenitor acute lymphoblastic leukemia (B-ALL), including Down syndrome (DS-ALL) patients, lacking recurring chromosomal translocations. Increased CRLF2 expression associates with JAK2 mutation, a combination that transforms hematopoietic cells, suggesting that mutant JAK2 and CRLF2 may cooperate to contribute to B-ALL formation. Importantly, elevated CRLF2 expression correlates with poor outcome in high-risk B-ALL patients. Therefore, CRLF2 may provide a new prognostic marker for high-risk B-ALL, and inhibition of CRLF2/JAK2 signaling may represent a therapeutic approach for this population of ALL patients.
authors.affiliation: Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
authors.forename: J Devon
authors.initials: JD
authors.lastname: Roll
authors.forename: Gary W
authors.initials: GW
authors.lastname: Reuther
mesh_terms: D000818:Animals; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D018121:Receptors, Cytokine / Q000235:genetics*
chemical_list: C498762:CRLF2 protein, human; D018121:Receptors, Cytokine; D053614:Janus Kinase 2
references.citation: Mucosal Immunol. 2010 Mar;3(2):138-47
references.pmid: 20016474
references.citation: Blood. 2009 Sep 24;114(13):2688-98
references.pmid: 19641190
references.citation: Blood. 2009 Jan 15;113(3):646-8
references.pmid: 18927438
references.citation: Lancet. 2008 Mar 22;371(9617):1030-43
references.pmid: 18358930
references.citation: Br J Haematol. 2009 Jan;144(2):147-56
references.pmid: 19006567
references.citation: Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18502-7
references.pmid: 18003935
references.citation: J Biol Chem. 2010 May 28;285(22):16651-63
references.pmid: 20363735
references.citation: Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8
references.pmid: 19470474
references.citation: J Immunol. 1999 Jan 15;162(2):677-83
references.pmid: 9916685
references.citation: Br J Haematol. 2009 Mar;144(6):930-2
references.pmid: 19120350
references.citation: J Biol Chem. 2009 Mar 13;284(11):6773-81
references.pmid: 19139102
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3716-21
references.pmid: 18559588
references.citation: Biochem Biophys Res Commun. 2001 Mar 9;281(4):878-83
references.pmid: 11237741
references.citation: Science. 2008 Nov 28;322(5906):1377-80
references.pmid: 19039135
references.citation: Blood. 2010 Feb 4;115(5):1006-17
references.pmid: 19965641
references.citation: J Immunol. 1999 Dec 1;163(11):5971-7
references.pmid: 10570284
references.citation: Cell Cycle. 2008 Mar 15;7(6):714-9
references.pmid: 18245948
references.citation: Nat Genet. 2009 Nov;41(11):1243-6
references.pmid: 19838194
references.citation: Adv Immunol. 2009;101:1-25
references.pmid: 19231591
references.citation: J Biol Chem. 2008 Feb 29;283(9):5258-66
references.pmid: 18158285
references.citation: Mol Cell Biol. 2004 Mar;24(6):2584-92
references.pmid: 14993294
references.citation: Nat Immunol. 2000 Jul;1(1):59-64
references.pmid: 10881176
references.citation: Leukemia. 2010 Mar;24(3):642-5
references.pmid: 19907440
references.citation: Lancet. 2008 Oct 25;372(9648):1484-92
references.pmid: 18805579
references.citation: Blood. 2010 Jul 1;115(26):5312-21
references.pmid: 20139093
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7
references.pmid: 20018760
references.citation: N Engl J Med. 2004 Apr 8;350(15):1535-48
references.pmid: 15071128